These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 22042629)

  • 21. Comparison of the pharmacological mechanisms involved in the platelet lowering actions of anagrelide and hydroxyurea: a review.
    Hong Y; Erusalimsky JD
    Platelets; 2002 Nov; 13(7):381-6. PubMed ID: 12487784
    [No Abstract]   [Full Text] [Related]  

  • 22. Toenails melanonychia induced by hydroxyurea.
    Kluger N; Naud M; Françès P
    Presse Med; 2012 Apr; 41(4):444-5. PubMed ID: 21996473
    [No Abstract]   [Full Text] [Related]  

  • 23. Hydroxyurea-induced melanonychia concomitant with a dermatomyositis-like eruption.
    Oh ST; Lee DW; Lee JY; Cho BK
    J Am Acad Dermatol; 2003 Aug; 49(2):339-41. PubMed ID: 12894095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Longitudinal melanonychia induced by hydroxyurea: four case reports and review of the literature.
    Delmas-Marsalet B; Beaulieu P; Teillet-Thiebaud F; Jary L; Teillet F
    Nouv Rev Fr Hematol (1978); 1995; 37(3):205-10. PubMed ID: 7567439
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cutaneous adverse reactions to hydroxyurea in patients with intermediate thalassemia.
    Zargari O; Kimyai-Asadi A; Jafroodi M
    Pediatr Dermatol; 2004; 21(6):633-5. PubMed ID: 15575845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Images in clinical medicine. Acquired melanonychia.
    Ranta D; Bonmati C
    N Engl J Med; 2009 Sep; 361(12):1188. PubMed ID: 19759381
    [No Abstract]   [Full Text] [Related]  

  • 27. Melanonychia.
    Charan S; Mishra K; Jandial A; Khadwal A; Malhotra P
    QJM; 2018 Dec; 111(12):909. PubMed ID: 29986101
    [No Abstract]   [Full Text] [Related]  

  • 28. Subungual melanoma complicated by hydroxyurea-induced melanonychia with non-melanoma Hutchinson's sign.
    Saito A; Fujisawa Y; Maruyama H; Nakamura Y; Ishitsuka Y; Watanabe R; Okiyama N; Fujimoto M
    Eur J Dermatol; 2018 Aug; 28(4):559-561. PubMed ID: 29941409
    [No Abstract]   [Full Text] [Related]  

  • 29. Mucocutaneous lesions and nail pigmentation in a patient with essential thrombocytosis.
    Calleja Algarra A; Miguel RA; Tous Romero F; Maroñas Jiménez L
    Aust Fam Physician; 2017; 46(4):222-224. PubMed ID: 28376576
    [No Abstract]   [Full Text] [Related]  

  • 30. Skin and nail changes in children with sickle cell anemia receiving hydroxyurea therapy.
    O'branski EE; Ware RE; Prose NS; Kinney TR
    J Am Acad Dermatol; 2001 May; 44(5):859-61. PubMed ID: 11312437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple pigmented nail bands during hydroxyurea therapy: an uncommon finding.
    Vomvouras S; Pakula AS; Shaw JM
    J Am Acad Dermatol; 1991 Jun; 24(6 Pt 1):1016-7. PubMed ID: 1869665
    [No Abstract]   [Full Text] [Related]  

  • 32. Multiple longitudinal pigmented nail bands during hydroxyurea therapy.
    Kelsey PR
    Clin Lab Haematol; 1992; 14(4):337-8. PubMed ID: 1478015
    [No Abstract]   [Full Text] [Related]  

  • 33. Longitudinal pigmented nail bands during hydroxyurea therapy.
    Cakir B; Sucak G; Haznedar R
    Int J Dermatol; 1997 Mar; 36(3):236-7. PubMed ID: 9159017
    [No Abstract]   [Full Text] [Related]  

  • 34. [Longitudinal melanonychia induced by hydroxyurea therapy].
    Neynaber S; Wolff H; Plewig G; Wienecke R
    J Dtsch Dermatol Ges; 2004 Jul; 2(7):588-91. PubMed ID: 16281621
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The pathogenesis and management of essential thrombocythaemia.
    Green AR
    Haematologica; 1999 Jun; 84 Suppl EHA-4():36-9. PubMed ID: 10907463
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia.
    Cacciola RR; Di Francesco E; Pezzella F; Tibullo D; Giustolisi R; Cacciola E
    Acta Haematol; 2007; 118(4):215-8. PubMed ID: 18057866
    [No Abstract]   [Full Text] [Related]  

  • 37. Toxicoderma caused by hydroxyurea.
    Serrano-Falcón C; Pugnaire MAF; Del Mar Serrano-Falcón M; Morales MG; Serrano-Ortega S
    Int J Dermatol; 2011 Nov; 50(11):1435-1437. PubMed ID: 22004505
    [No Abstract]   [Full Text] [Related]  

  • 38. Mucocutaneous adverse effects of hydroxyurea: a prospective study of 30 psoriasis patients.
    Kumar B; Saraswat A; Kaur I
    Clin Exp Dermatol; 2002 Jan; 27(1):8-13. PubMed ID: 11952660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hydroxyurea in sickle cell disease.
    Adams-Graves P; Heltsley C; Deitcher S
    N Engl J Med; 1996 Feb; 334(5):333-4. PubMed ID: 8532043
    [No Abstract]   [Full Text] [Related]  

  • 40. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
    Harrison CN; Campbell PJ; Buck G; Wheatley K; East CL; Bareford D; Wilkins BS; van der Walt JD; Reilly JT; Grigg AP; Revell P; Woodcock BE; Green AR;
    N Engl J Med; 2005 Jul; 353(1):33-45. PubMed ID: 16000354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.